To: All Concerned Parties | May 6, 2021 |
Company Name: Solasia Pharma K.K. | |
Representative: | Yoshihiro Arai, President & CEO |
(Code number: | 4597, TSE Mothers Section) |
Contact: | Toshio Miyashita, CFO, Director |
Tel: | 81-3-5843-8049 |
URL: | https://solasia.co.jp/en/ |
Solasia's Partner, Isofol Announces Global Phase III AGENT Study for
arfolitixorin(SP-05) Completed Recruitment of Japanese Patients
Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announced that the global phase III AGENT study for arfolitixorin(SP-05) has completed the recruitment of Japanese patients in accordance with the regulatory requirements by the PMDA (the Japanese Medicines Agency) to reach market approval in Japan.
For more information, please refer to the following URL link to Isofol´s website. https://isofolmedical.com/
###
Attachments
- Original document
- Permalink
Disclaimer
Solasia Pharma KK published this content on 06 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2021 18:28:03 UTC.